I’m kind of in grant writing hell at the moment, as many of you may have been at various times, but I’m still finding time to read a little on cell therapy and stem cell research. Here are some things that caught my eye as I work on multiple grants with impending deadlines. Clinical trials […]
Weekly reads: cell therapy trials, melanoma, β-thalassemia Read More »
I often get asked about where things stand with stem cell therapy for back pain, which is the focus of today’s post. Back pain is a complex condition with many potential causes. New treatments are needed as existing approaches often don’t work that well. What about stem cells? Stem cell therapy or other cell therapy
Can stem cell therapy for back pain work? Read More »
Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes
Where Kimera Labs fits into sphere of exosome companies Read More »
I usually associate NPR with solid journalism so I was scratching my head about a recent puff piece by WHYY on stem cell microneedling. Is this journalism or product promotion? The NPR piece by Maiken Scott doesn’t ask important questions. Scott received stem cell microneedling herself using a product from a company called AnteAGE. How
WHYY oh WHYY: NPR puff piece on risky stem cell microneedling Read More »
Are there endogenous adult heart stem cells that are useful in cardiac disease or can stem cell infusions help ailing hearts? As to the first question, the adult heart does not appear to have meaningful numbers of true stem cells. Further, testing the idea of infusions of stem cells for heart disease has so far been giving
Heart stem cells trial mostly disappoints but is oversold Read More »
Occasionally when I write a post there is an angry reaction to it in the blog comments, which was the case for my recent fact-check of the LifeWave X39 patches. As you can see in that post, I didn’t find convincing data to either back up the claimed stem cell connection. In my opinion, there
Weekly reads: bat stem cells & viruses, Lineage Cell, He Jiankui visa Read More »
What is the cell therapy for ALS called NurOwn? How strong is its potential as a treatment for ALS? I’ve been following the biotech BrainStorm Cell Therapeutics for many years. Patients keep asking me about NurOwn ALS prospects. They’re looking for hope. Today’s post is a close look at NurOwn and at BrainStorm as a
Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS? Read More »
Let’s start with a couple of new pieces on in vivo reprogramming. The idea here is to do something like making iPS cells but doing it inside organisms and not quite pushing cells all the way back to pluripotency. Just younger, healthier cells. Why do that? The goal is to achieve a kind of anti-aging
Weekly reads: reprogramming aging, astrocytes, cartilage, ChatGPT Read More »
It’s that time of year again when I grade my previous year’s predictions for the stem cell & regenerative medicine space. Overall, I did better than a typical year. I give the 2022 predictions an A- overall. This exercise can be kind of fun but also humbling. For example, I tend to be too optimistic
Grading my 2022 regenerative medicine predictions Read More »
Stem cell stroke therapy research has generated buzz over the years. The goal of today’s post is to fact-check claims about supposed stem cell stroke therapies and educate readers on where clinical research stands. There is some real hope here in the long run, but things have been greatly exaggerated at times. Some clinics are
Fact-checking stem cell stroke therapy: hope but not there yet Read More »